Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non–small-cell lung cancer
    Meeting Abstract

    Johnson, M. L.; Henry, J. T.; Spira, A. I.; Battiste, J.; Alnahhas, I.; Ahluwalia, M. S.; Barve, M. A.; Edenfield, W. J.; Nam, D. H.; Eathiraj, S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM)
    Meeting Abstract

    Davar, D.; Ikeguchi, A.; Buchbinder, E. I.; Shoushtari, A. N.; Seedor, R. S.; Bernicker, E.; Weiss, S. A.; Daniels, G. A.; Panella, T. J.; Ryan, H. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2
    Meeting Abstract

    Sehn, L. H.; Chamuleau, M.; Lenz, G.; Clausen, M.; Haioun, C.; Izutsu, K.; Davies, A. J. J.; Zhu, J.; Oki, T.; Szafer-Glusman, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)
    Meeting Abstract

    Berdeja, J. G.; Martin, T. G.; Rossi, A.; Essell, J. H.; Siegel, D. S. D.; Mailankody, S.; Saini, N.; Holmes, H.; Dhakal, B.; Gasparetto, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent
    Meeting Abstract

    Kumar, S.; Bachier, C. R.; Cavo, M.; Corradini, P.; Delforge, M.; Janowski, W.; Lesokhin, A. M.; Mina, R.; Paris, L.; Rosiñol, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma
    Meeting Abstract

    Vergote, I.; Mirza, M. R.; Coleman, R. L.; Perez-Fidalgo, J. A.; Monk, B. J.; Valabrega, G.; Slomovitz, B. M.; Van Gorp, T.; Moore, K. N.; Sehouli, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2 open-label study of conditionally active biologic ozuriftamab vedotin (BA3021) in failed PD-1/L1 treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Meeting Abstract

    Ho, A. L.; Adkins, D.; Lorch, J. H.; Thomas, J. S.; Grewal, J. S.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 1/2 dose escalation study of the BCL-2 inhibitor ZN-d5 and the WEE1 inhibitor azenosertib (ZN-c3) in patients (Pts) with acute myeloid leukemia (AML)
    Meeting Abstract

    Smith, C. C.; Vachhani, P.; Garcia-Manero, G.; Grieselhuber, N. R.; Guru Murthy, G. S.; Bhatia, A.; Arora, J.; Izadi, H.; Fiorino, A.; Rampal, R.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save